{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:22Z","timestamp":1794020002651,"version":"4.8.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001797.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000}}],"reference-count":108,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001797.pub4","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T06:50:11Z","timestamp":1707893411000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy"],"prefix":"10.1002","volume":"2024","author":[{"given":"Sander RM","family":"Bus","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience; Amsterdam UMC, University of Amsterdam; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J","family":"de Haan","sequence":"additional","affiliation":[{"name":"Clinical Research Unit; Amsterdam UMC, University of Amsterdam; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience; Amsterdam UMC, University of Amsterdam; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo N","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience; Amsterdam UMC, University of Amsterdam; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam Neuroscience; Amsterdam UMC, University of Amsterdam; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"issue":"10 Suppl","key":"10.1002\/14651858.CD001797.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"P7.092","DOI":"10.1212\/WNL.82.10_supplement.P7.092","article-title":"Multicentre, randomised, open-label trial to compare efficacy and tolerance of prednisone and IVIG In patients with CIDP on a one year follow up (P7.092)","volume":"82","author":"Camdessanche","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001797.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Annals of Neurology"},{"issue":"Part 4","key":"10.1002\/14651858.CD001797.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","article-title":"Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001797.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001797.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00868527","article-title":"A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"243","author":"Thompson","year":"1996","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study","volume":"56","author":"Vermeulen","year":"1993","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD001797.pub4-BIB0010|cit10","first-page":"1336","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"36","author":"Baba","year":"1996","journal-title":"Clinical Neurology"},{"issue":"5","key":"10.1002\/14651858.CD001797.pub4-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1212\/NXI.0000000000000586","article-title":"Intravenous immunoglobulin for treatment of demyelinating polyneuropathy in patients with diabetes mellitus: a randomized, double-blinded, placebo-controlled crossover trial","volume":"6","author":"Breiner","year":"2019","journal-title":"Neurology Neuroimmunology Neuroinflammation"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"Cornblath","year":"2022","journal-title":"Brain"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0013|cit13","unstructured":"Study to evaluate safety and efficacy of three different dosages of NewGam in patients with chronic inflammatory demyelinating poly (radiculo) neuropathy (CIDP) clinicaltrials.gov\/study\/NCT02638207"},{"issue":"4","key":"10.1002\/14651858.CD001797.pub4-BIB0014|cit14","first-page":"321","article-title":"High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy","volume":"8","author":"Curro","year":"1987","journal-title":"Italian Journal of Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD001797.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0016|cit16","unstructured":"A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg\u00ae versus T\u00e9g\u00e9line\u00ae in maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) clinicaltrialsregister.eu\/ctr-search\/trial\/2012-001996-34\/FR"},{"issue":"9","key":"10.1002\/14651858.CD001797.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/jnnp.57.9.1137","article-title":"An 'n of 1' trial of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy","volume":"57","author":"Hankey","year":"1994","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Intravenous immunoglobulin overtreatment in chronic inflammatory demyelinating polyneuropathy isrctn.com\/ISRCTN13637698 https:\/\/doi.org\/10.1186\/ISRCTN13637698","DOI":"10.1186\/ISRCTN13637698"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0019|cit19","first-page":"127","article-title":"The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy","volume":"51","author":"Kubori","year":"1999","journal-title":"Brain & Nerve"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/ene.14501","article-title":"Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Kuitwaard","year":"2021","journal-title":"European Journal of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD001797.pub4-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1136\/jnnp-2017-316427","article-title":"Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial","volume":"88","author":"Kuwabara","year":"2017","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/jns5.12017","article-title":"Efficacy and safety of Privigen in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)","volume":"18","author":"L\u00e9ger","year":"2013","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/ene.13218","article-title":"Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study","volume":"24","author":"Markvardsen","year":"2017","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0024|cit24","unstructured":"Safety and efficacy study of three different dosages of NewGam in patients with CIDP (POINT) clinicaltrials.gov\/show\/NCT01225276"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0025|cit25","unstructured":"Single vs. multiple Privigen dose regimens in pediatric CIDP clinicaltrials.gov\/ct2\/show\/NCT03684018"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001797.pub4-BIB0026|cit26","first-page":"737, Abstract n","article-title":"CIDP - intravenous immunoglobulin or corticosteroids?","volume":"23","author":"Neacsu","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.40.2.209","article-title":"High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study","volume":"40","author":"Doorn","year":"1990","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.transci.2005.07.010","article-title":"A pilot study to compare the use of Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy","volume":"33","author":"Zinman","year":"2005","journal-title":"Transfusion and Apheresis Science"},{"issue":"24","key":"10.1002\/14651858.CD001797.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1002\/sim.2423","article-title":"Meta-analysis of heterogeneously reported trials assessing change from baseline","volume":"24","author":"Abrams","year":"2005","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001797.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.41.5.617","article-title":"Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"41","author":"Ad hoc subcommittee of the American Academy of Neurology AIDS Task Force","year":"1991","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD001797.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archneur.1989.00520440064022","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria","volume":"46","author":"Barohn","year":"1989","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0032|cit32","first-page":"190","article-title":"Long term treatment of chronic inflammatory demyelinating polyradiculoneuropathy: combinations of corticosteroids, plasma exchange, and intravenous immunoglobulin","volume":"39","author":"Briellmann","year":"1998","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2377-14-26","article-title":"Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review","volume":"14","author":"Bright","year":"2014","journal-title":"BMC Neurology"},{"issue":"3-4","key":"10.1002\/14651858.CD001797.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000494291","article-title":"Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"52","author":"Broers","year":"2019","journal-title":"Neuroepidemiology"},{"issue":"10","key":"10.1002\/14651858.CD001797.pub4-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014542","article-title":"Subcutaneous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Bus","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD001797.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1136\/jnnp.2007.114868","article-title":"Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy","volume":"78","author":"Chi\u00f2","year":"2007","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.410300119","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin","volume":"30","author":"Cornblath","year":"1991","journal-title":"Annals of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD001797.pub4-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/1352458509106710","article-title":"Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks","volume":"15","author":"Cr\u00e9ange","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1161\/01.STR.24.2.320","article-title":"Measuring quality of life in stroke","volume":"24","author":"Haan","year":"1993","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0040|cit40","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ana.410170112","article-title":"Ocular palsy preceding chronic relapsing polyneuropathy by several weeks","volume":"17","author":"Donaghy","year":"1985","journal-title":"Annals of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001797.pub4-BIB0042|cit42","first-page":"79","article-title":"Side-effects of intravenous immune globulins","volume":"97","author":"Duhem","year":"1994","journal-title":"Clinical & Experimental Immunology"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD001797.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001797.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1212\/WNL.42.6.1164","article-title":"The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity","volume":"42","author":"Dyck","year":"1992","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0046|cit46","first-page":"1498","volume-title":"Peripheral Neuropathy","author":"Dyck","year":"1993"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0048|cit48","unstructured":"A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg\u00ae versus T\u00e9g\u00e9line\u00ae in maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) CNO - CN-01848101 trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-001996-34-FR"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/WNL.39.3.422","article-title":"High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy","volume":"39","author":"Faed","year":"1989","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0733-8619(18)30202-0","article-title":"Inflammatory demyelinating polyneuropathies","volume":"10","author":"Feasby","year":"1992","journal-title":"Neurologic Clinics"},{"issue":"7","key":"10.1002\/14651858.CD001797.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0052|cit52","first-page":"154","article-title":"Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"4","author":"Gaebel","year":"2010","journal-title":"Open Medicine"},{"issue":"8","key":"10.1002\/14651858.CD001797.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome","volume":"35","author":"The Guillain-Barr\u00e9 Syndrome Study Group","year":"1985","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0022-510X(81)90135-0","article-title":"The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange","volume":"52","author":"Gross","year":"1981","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain\u2013Barr\u00e9 syndrome","volume":"35","author":"The Guillain-Barr\u00e9 Syndrome Study Group","year":"1985","journal-title":"Neurology"},{"issue":"6 Suppl 5","key":"10.1002\/14651858.CD001797.pub4-BIB0056|cit56","first-page":"16","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin","volume":"51","author":"Hahn","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0057|cit57","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0058|cit58","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated March 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0059|cit59","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0060|cit60","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0061|cit61","unstructured":"Higgins J Lasserson T Chandler J Tovey D Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews (MECIR). Standards for the conduct and reporting of new Cochrane Intervention Reviews, reporting of protocols and the planning, conduct and reporting of updates. Version February 2022. Cochrane, 2022 Available at community.cochrane.org\/sites\/default\/files\/uploads\/MECIR%20Version%20February%202022.pdf"},{"issue":"6","key":"10.1002\/14651858.CD001797.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1212\/WNL.0000000000008742","article-title":"Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD001797.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory disease with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD001797.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneurol.2010.105","article-title":"Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Latov","year":"2010","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0733-8619(05)70012-8","article-title":"Treatment approaches for Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","volume":"19","author":"Lindenbaum","year":"2001","journal-title":"Neurologic Clinics"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archneur.62.2.249","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone","volume":"62","author":"Lopate","year":"2005","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD001797.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/jnnp.66.5.677","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England","volume":"66","author":"Lunn","year":"1999","journal-title":"Journal of Neurology Neurosurgery & Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/jns.12158","article-title":"A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies","volume":"21","author":"Lunn","year":"2016","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"6","key":"10.1002\/14651858.CD001797.pub4-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003280.pub4","article-title":"Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Mahdi-Rogers","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0071|cit71","first-page":"181","volume-title":"Treatment of neurological disorders with intravenous immunoglobulins","author":"Martin","year":"2000"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0022-510X(94)90070-1","article-title":"Chronic inflammatory demyelinating polyneuropathy: histological and immunopathological studies on biopsied sural nerves","volume":"127","author":"Matsumuro","year":"1994","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD001797.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","article-title":"Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"McCrone","year":"2003","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001797.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/1531-8249(199912)46:6<910::AID-ANA14>3.0.CO;2-2","article-title":"Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia","volume":"46","author":"McLeod","year":"1999","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD001797.pub4-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002062.pub2","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Hughes","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD001797.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1212\/WNL.54.4.943","article-title":"Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group","volume":"54","author":"Merkies","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jns.12302","article-title":"Efficacy and safety of IVIG in CIDP: combined data of the PRIMA and PATH studies","volume":"24","author":"Merkies","year":"2019","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/jnnp.64.1.84","article-title":"Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy","volume":"64","author":"Molenaar","year":"1998","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD001797.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archneur.65.11.1460","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids","volume":"65","author":"Muley","year":"2008","journal-title":"Archives of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001797.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","article-title":"Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP","volume":"86","author":"Nobile-Orazio","year":"2015","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mus.880100304","article-title":"A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies","volume":"10","author":"Pollard","year":"1987","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1002\/14651858.CD001797.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1529-8027.2006.00105.x","article-title":"Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy","volume":"11","author":"Rajabally","year":"2006","journal-title":"Journal of the Peripheral Nervous System"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0083|cit83","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","author":"RMC Trial Group","year":"2009","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1212\/01.wnl.0000167549.09664.b8","article-title":"Distinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations","volume":"65","author":"Ruts","year":"2005","journal-title":"Neurology"},{"issue":"21","key":"10.1002\/14651858.CD001797.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0087|cit87","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"4","key":"10.1002\/14651858.CD001797.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.880050405","article-title":"Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy","volume":"5","author":"Scott","year":"1982","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410060313","article-title":"Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange","volume":"6","author":"Server","year":"1979","journal-title":"Annals of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD001797.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1212\/WNL.43.11.2202","article-title":"Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients without and with monoclonal gammopathy","volume":"43","author":"Simmons","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001797.pub4-BIB0091|cit91","first-page":"193","volume-title":"Intravenous immunoglobulin: research and therapy","author":"Stiehm","year":"1996"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"European Journal of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD001797.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"European Journal of Neurology"},{"issue":"Pt 6","key":"10.1002\/14651858.CD001797.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/brain\/112.6.1563","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"112","author":"Mech\u00e9","year":"1989","journal-title":"Brain"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000113378","article-title":"Future developments in the treatment of immune-related polyneuropathies","volume":"38","author":"Mech\u00e9","year":"1997","journal-title":"European Neurology"},{"issue":"1-3","key":"10.1002\/14651858.CD001797.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0165-5728(90)90147-F","article-title":"On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy","volume":"29","author":"Doorn","year":"1990","journal-title":"Journal of Neuroimmunology"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1991.00530140113024","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy","volume":"48","author":"Doorn","year":"1991","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1529-8027.2008.00169.x","article-title":"Outcome measure in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials","volume":"13","author":"Nes","year":"2008","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"Suppl","key":"10.1002\/14651858.CD001797.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.57.Suppl.15","article-title":"In vitro effects of polyvalent immunoglobulin for intravenous use","volume":"57","author":"Schaik","year":"1994","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"Schaik","year":"2010","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Schaik","year":"2018","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-510X(85)90173-X","article-title":"Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy","volume":"70","author":"Vermeulen","year":"1985","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0103|cit103","first-page":"43","article-title":"Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS\/WHO meeting","volume":"60","year":"1982","journal-title":"Bulletin of the World Health Organization"},{"issue":"3","key":"10.1002\/14651858.CD001797.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD001797.pub4-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001797.pub3","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Eftimov","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD001797.pub4-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Van Schaik","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001797.pub4-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Van Schaik","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001797.pub4-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001797.pub2","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Eftimov","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:13:19Z","timestamp":1748326399000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001797.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":108,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001797.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]}}}